Post-Marketing Safety Surveillance of HPV Vaccines in Anhui Province, China, 2017–2024
Abstract
1. Introduction
2. Materials and Methods
2.1. Data Collection
2.2. Types of HPV Vaccines and Vaccination Procedures
2.3. Definition and Categorization of AEFIs
2.4. Monitoring Method
2.5. Statistical Analysis
3. Results
3.1. HPV Vaccines Administration
3.2. Classification of AEFIs
3.3. Distributional Characteristics of AEFIs
3.4. Clinical Diagnosis of Common Adverse Reactions
3.5. Clinical Diagnosis of Rare Adverse Reactions
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Arbyn, M.; Weiderpass, E.; Bruni, L.; de Sanjosé, S.; Saraiya, M.; Ferlay, J.; Bray, F. Estimates of Incidence and Mortality of Cervical Cancer in 2018: A Worldwide Analysis. Lancet Glob. Health 2020, 8, e191–e203. [Google Scholar] [CrossRef]
- Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 2024, 74, 229–263. [Google Scholar] [CrossRef] [PubMed]
- Ferlay, J.; Ervik, M.; Lam, F.; Laversanne, M.; Colombet, M.; Mery, L.; Piñeros, M.; Znaor, A.; Soerjomataram, I.; Bray, F. Global Cancer Observatory: Cancer Today; International Agency for Research on Cancer: Lyon, France, 2024; Available online: https://gco.iarc.who.int/media/globocan/factsheets/cancers/23-cervix-uteri-fact-sheet.pdf (accessed on 7 March 2025).
- Luo, Y.; Wang, X.R.; Zhang, F.M.; Dong, Y.Z.; Zhu, Y.N. Research status in application and safety research of preventive human papillomavirus vaccine. Chin. J. Clin. Pharmacol. 2024, 40, 2586–2590. [Google Scholar] [CrossRef]
- Chen, Q.; Wu, T.; Zhang, J.; Xia, N.S. Development and application of prophylactic human papilloma virus vaccines in China. Chin. J. Dis. Control. Prev. 2023, 27, 249–253. [Google Scholar] [CrossRef]
- Li, M.; Zhao, C.; Zhao, Y.; Li, J.; Wei, L. Immunogenicity, Efficacy, and Safety of Human Papillomavirus Vaccine: Data from China. Front. Immunol. 2023, 14, 1112750. [Google Scholar] [CrossRef] [PubMed]
- Ministry of Health of China, State Food and Drug Administration of, China. Notice on the Issuance of the National Program for Monitoring Adverse Events Following Immunization (AEFI). Available online: https://www.nmpa.gov.cn/xxgk/fgwj/qita/20100603120001618.html (accessed on 25 February 2025).
- Anhui Provincial Bureau of Statistics. Anhui Provincial Population Census Yearbook 2020. Available online: https://tjj.ah.gov.cn/ssah/qwfbjd/tjnj/ahrkpc2020ebook/index.htm (accessed on 7 March 2025).
- Lei, J.; Ploner, A.; Elfström, K.M.; Wang, J.; Roth, A.; Fang, F.; Sundström, K.; Dillner, J.; Sparén, P. HPV Vaccination and the Risk of Invasive Cervical Cancer. N. Engl. J. Med. 2020, 383, 1340–1348. [Google Scholar] [CrossRef]
- Canfell, K.; Kim, J.J.; Brisson, M.; Keane, A.; Simms, K.T.; Caruana, M.; Burger, E.A.; Martin, D.; Nguyen, D.T.N.; Bénard, É.; et al. Mortality Impact of Achieving WHO Cervical Cancer Elimination Targets: A Comparative Modelling Analysis in 78 Low-Income and Lower-Middle-Income Countries. Lancet 2020, 395, 591–603. [Google Scholar] [CrossRef]
- Chen, J.; Zhang, Z.; Pan, W.; Song, Y.; Zheng, L.; Li, L.; Ye, J.; Cao, L.; Yu, W. Estimated Human Papillomavirus Vaccine Coverage Among Females 9-45 Years of Age—China, 2017-2022. China CDC Wkly. 2024, 6, 413–417. [Google Scholar] [CrossRef]
- Kaur, G.; Danovaro-Holliday, M.C.; Mwinnyaa, G.; Gacic-Dobo, M.; Francis, L.; Grevendonk, J.; Sodha, S.V.; Sugerman, C.; Wallace, A. Routine Vaccination Coverage—Worldwide, 2022. MMWR Morb. Mortal. Wkly. Rep. 2023, 72, 1155–1161. [Google Scholar] [CrossRef]
- You, D.; Han, L.; Li, L.; Hu, J.; Zimet, G.D.; Alias, H.; Danaee, M.; Cai, L.; Zeng, F.; Wong, L.P. Human Papillomavirus (HPV) Vaccine Uptake and the Willingness to Receive the HPV Vaccination among Female College Students in China: A Multicenter Study. Vaccines 2020, 8, 31. [Google Scholar] [CrossRef]
- Hu, S.; Xu, X.; Zhang, Y.; Liu, Y.; Yang, C.; Wang, Y.; Wang, Y.; Yu, Y.; Hong, Y.; Zhang, X.; et al. A Nationwide Post-Marketing Survey of Knowledge, Attitude and Practice toward Human Papillomavirus Vaccine in General Population: Implications for Vaccine Roll-out in Mainland China. Vaccine 2021, 39, 35–44. [Google Scholar] [CrossRef]
- Zhang, J.X. HPV Vaccine Free Vaccination Policy Has Covered 40% of Eligible Girls. Sci. Technol. Dly. 2024, 002. [Google Scholar] [CrossRef]
- Zhang, L.N.; Li, K.L.; Li, Y.; Fan, C.X.; Li, Y.; Ren, M.R.; Yin, Z.D. Surveillance for adverse events following immunization with human papillomavirus vaccines in China, 2017–2020. Chin. J. Vaccines Immun. 2023, 29, 451–457. [Google Scholar] [CrossRef]
- Zhou, K.J.; Zhao, Z.J.; Liang, W.J. Analysis on surveillance of adverse events following immunization of human papillomavirus vaccine in Guangdong, 2018–2020. South China J. Prev. Med. 2022, 48, 707–710. [Google Scholar]
- Wang, J.H.; Sun, L.; Wang, S.F.; Wang, Y.H.; Li, J.; Cui, S.H.; Xu, X.M.; Guo, Y. Surveillance analysis of adverse events following immunization with the bivalent human papillomavirus vaccine and recombinant human papillomavirus 9-valent vaccine in Hebei province from 2018 to 2022. Chin. J. Public Health 2024, 40, 1110–1116. [Google Scholar]
- Zheng, M.; Wu, F.Y.; Zhao, H.P.; Tan, X.Y.; Guo, S.C. Surveillance of adverse events following immunization with human papilloma virus vaccine in Jiangxi, 2017–2022. Mod. Prev. Med. 2024, 51, 748–751. [Google Scholar] [CrossRef]
- Shimabukuro, T.T.; Su, J.R.; Marquez, P.L.; Mba-Jonas, A.; Arana, J.E.; Cano, M.V. Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics 2019, 144, e20191791. [Google Scholar] [CrossRef]
- Di Lorenzo, A.; Berardi, P.; Martinelli, A.; Bianchi, F.P.; Tafuri, S.; Stefanizzi, P. Real-Life Safety Profile of the 9-Valent HPV Vaccine Based on Data from the Puglia Region of Southern Italy. Vaccines 2022, 10, 419. [Google Scholar] [CrossRef]
- Phillips, A.; Hickie, M.; Totterdell, J.; Brotherton, J.; Dey, A.; Hill, R.; Snelling, T.; Macartney, K. Adverse Events Following HPV Vaccination: 11 Years of Surveillance in Australia. Vaccine 2020, 38, 6038–6046. [Google Scholar] [CrossRef]
- Egoavil, C.M.; Tuells, J.; Carreras, J.J.; Montagud, E.; Pastor-Villalba, E.; Caballero, P.; Nolasco, A. Trends of Adverse Events Following Immunization (AEFI) Reports of Human Papillomavirus Vaccine in the Valencian Community-Spain (2008–2018). Vaccines 2020, 8, 117. [Google Scholar] [CrossRef]
- Dey, A.; Wang, H.; Quinn, H.; Pillsbury, A.; Hickie, M.; Deng, L.; Wood, N.; Beard, F.; Macartney, K. Surveillance of Adverse Events Following Immunisation in Australia Annual Report, 2020. Commun. Dis. Intell. (2018) 2022, 46. [Google Scholar] [CrossRef]
- An, J.; Liu, Y.; Ma, Y.; Jiao, Y.-Z.; Liang, X.-F.; Jin, N.; Bao, J.; Jiang, N.; Zhang, X.-S. Real-World Data of China: Analysis of HPV Vaccine Coverage and Post-Vaccination Adverse Reaction Monitoring in Western Chinese Provinces from 2018 to 2021. Hum. Vaccin. Immunother. 2024, 20, 2315653. [Google Scholar] [CrossRef]
- Fan, Z.J.; Li, F.; Xu, H.Y.; Wang, X.L.; Yuan, H.; Meng, Q.Y.; Wang, M.; Wang, R.; Wang, Y.R.; Yao, Y.Y.; et al. Monitoring results of adverse events following immunization of human papillomavirus vaccine in Zhengzhou city from 2019 to 2022. Mod. Dis. Control Prev. 2024, 35, 313–317. [Google Scholar] [CrossRef]
- Lingnan Cervical Cancer Prevention and Control Alliance of the Third Affiliated Hospital of Sun Yat-sen University; Professional Committee on Cervical Cancer Prevention and Control of Guangdong Preventive Medicine Association. Chinese expert consensuson the safety of human papillomavirus vaccination. J. Chin. Physician 2023, 25, 1644–1660. [Google Scholar] [CrossRef]
Type | Common Adverse Reaction | Rare Adverse Reaction | Psychogenic Reaction | Coincidental Event | Pending Event | Total | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
No. | Incidence * | No. | Incidence | No. | Incidence | No. | Incidence | No. | Incidence | No. | Incidence | |
HPV2 (adsorbed) | 79 | 20.87 | 7 | 1.85 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 86 | 22.71 |
HPV2 (E. coli) | 298 | 13.01 | 12 | 0.52 | 2 | 0.09 | 0 | 0.00 | 0 | 0.00 | 312 | 13.62 |
HPV2 (P. pastoris) | 29 | 34.18 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 29 | 34.18 |
HPV4 (S. cerevisiae) | 193 | 11.52 | 19 | 1.13 | 2 | 0.12 | 3 | 0.18 | 0 | 0.00 | 217 | 12.95 |
HPV9 (S. cerevisiae) | 467 | 17.91 | 22 | 0.84 | 8 | 0.31 | 7 | 0.27 | 1 | 0.04 | 505 | 19.36 |
Total | 1066 | 15.15 | 60 | 0.85 | 12 | 0.17 | 10 | 0.14 | 1 | 0.01 | 1149 | 16.32 |
Characteristics | HPV2 (Adsorbed) | HPV2 (E. coli) | HPV2 (P. pastoris) | HPV4 (S. cerevisiae) | HPV9 (S. cerevisiae) | Total | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
No. | Proportion | No. | Proportion | No. | Proportion | No. | Proportion | No. | Proportion | No. | Proportion | |
(%) | (%) | (%) | (%) | (%) | (%) | |||||||
Age | ||||||||||||
9–17 | 13 | 15.12 | 27 | 8.65 | 9 | 31.03 | 5 | 2.30 | 79 | 15.64 | 133 | 11.58 |
18–26 | 2 | 2.33 | 13 | 4.17 | 7 | 24.14 | 11 | 5.07 | 242 | 47.92 | 275 | 23.93 |
≥27 | 71 | 82.56 | 272 | 87.18 | 13 | 44.83 | 201 | 92.63 | 184 | 36.44 | 741 | 64.49 |
Quarter | ||||||||||||
1 | 12 | 13.95 | 90 | 28.85 | 11 | 37.93 | 41 | 18.89 | 89 | 17.62 | 243 | 21.15 |
2 | 21 | 24.42 | 68 | 21.79 | 6 | 20.69 | 66 | 30.41 | 151 | 29.90 | 312 | 27.15 |
3 | 27 | 31.40 | 60 | 19.23 | 7 | 24.14 | 51 | 23.50 | 144 | 28.51 | 289 | 25.15 |
4 | 26 | 30.23 | 94 | 30.13 | 5 | 17.24 | 59 | 27.19 | 121 | 23.96 | 305 | 26.54 |
Dose | ||||||||||||
1 | 41 | 47.67 | 132 | 42.31 | 16 | 55.17 | 104 | 47.93 | 286 | 56.63 | 579 | 50.39 |
2 | 23 | 26.74 | 83 | 26.60 | 3 | 10.34 | 58 | 26.73 | 104 | 20.59 | 271 | 23.59 |
3 | 22 | 25.58 | 97 | 31.09 | 10 | 34.48 | 55 | 25.35 | 115 | 22.77 | 299 | 26.02 |
Time Interval | ||||||||||||
≤1 | 74 | 86.05 | 282 | 90.38 | 29 | 100.00 | 190 | 87.56 | 425 | 84.16 | 1000 | 87.03 |
2–7 | 8 | 9.30 | 26 | 8.33 | 0 | 0.00 | 19 | 8.76 | 44 | 8.71 | 97 | 8.44 |
8–14 | 2 | 2.33 | 3 | 0.96 | 0 | 0.00 | 3 | 1.38 | 8 | 1.58 | 16 | 1.39 |
≥15 | 2 | 2.33 | 1 | 0.32 | 0 | 0.00 | 5 | 2.30 | 28 | 5.54 | 36 | 3.13 |
Serious AEFI | ||||||||||||
No | 85 | 98.84 | 310 | 99.36 | 29 | 100.00 | 210 | 96.77 | 500 | 99.01 | 1134 | 98.69 |
Yes | 1 | 1.16 | 2 | 0.64 | 0 | 0.00 | 7 | 3.23 | 5 | 0.99 | 15 | 1.31 |
Total | 86 | 100.00 | 312 | 100.00 | 29 | 100.00 | 217 | 100.00 | 505 | 100.00 | 1149 | 100.00 |
Clinical Diagnosis | HPV2 (Adsorbed) | HPV2 (E. coli) | HPV2 (P. pastoris) | HPV4 (S. cerevisiae) | HPV9 (S. cerevisiae) | Total | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
No. | Incidence * | No. | Incidence | No. | Incidence | No. | Incidence | No. | Incidence | No. | Incidence | |
Common Adverse Reaction | ||||||||||||
Fever (Axillary, °C) | 43 | 11.36 | 96 | 4.19 | 11 | 12.96 | 72 | 4.30 | 192 | 7.36 | 414 | 5.88 |
37.1–37.5 | 19 | 5.02 | 38 | 1.66 | 6 | 7.07 | 38 | 2.27 | 73 | 2.80 | 174 | 2.47 |
37.6–38.5 | 16 | 4.23 | 31 | 1.35 | 1 | 1.18 | 21 | 1.25 | 77 | 2.95 | 146 | 2.07 |
≥38.6 | 8 | 2.11 | 27 | 1.18 | 4 | 4.71 | 13 | 0.78 | 42 | 1.61 | 94 | 1.34 |
Swelling (Diameter, cm) | 34 | 8.98 | 175 | 7.64 | 18 | 21.21 | 109 | 6.51 | 226 | 8.66 | 562 | 7.98 |
≤2.5 | 10 | 2.64 | 92 | 4.02 | 11 | 12.96 | 52 | 3.10 | 112 | 4.29 | 277 | 3.94 |
2.6–5.0 | 18 | 4.75 | 69 | 3.01 | 6 | 7.07 | 53 | 3.16 | 97 | 3.72 | 243 | 3.45 |
>5.0 | 6 | 1.58 | 14 | 0.61 | 1 | 1.18 | 4 | 0.24 | 17 | 0.65 | 42 | 0.60 |
Induration (Diameter, cm) | 29 | 7.66 | 130 | 5.67 | 11 | 12.96 | 73 | 4.36 | 146 | 5.60 | 389 | 5.53 |
≤2.5 | 9 | 2.38 | 65 | 2.84 | 7 | 8.25 | 37 | 2.21 | 83 | 3.18 | 201 | 2.86 |
2.6–5.0 | 18 | 4.75 | 57 | 2.49 | 4 | 4.71 | 33 | 1.97 | 53 | 2.03 | 165 | 2.34 |
>5.0 | 2 | 0.53 | 8 | 0.35 | 0 | 0.00 | 3 | 0.18 | 10 | 0.38 | 23 | 0.33 |
Other Common Adverse Reaction | 3 | 0.79 | 26 | 1.13 | 2 | 2.36 | 18 | 1.07 | 57 | 2.19 | 106 | 1.51 |
Rare Adverse Reaction | 7 | 1.85 | 12 | 0.52 | 0 | 0.00 | 19 | 1.13 | 22 | 0.84 | 60 | 0.85 |
Allergic Reaction | 5 | 1.32 | 10 | 0.44 | 0 | 0.00 | 15 | 0.90 | 19 | 0.73 | 49 | 0.70 |
Neurologic diseases | 1 | 0.26 | 1 | 0.04 | 2 | 0.12 | 4 | 0.06 | ||||
Henoch–Schönlein purpura | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 1 | 0.04 | 1 | 0.01 |
Aseptic abscess | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 2 | 0.08 | 2 | 0.03 |
Others | 1 | 0.26 | 1 | 0.04 | 0 | 0.00 | 2 | 0.12 | 0 | 0.00 | 4 | 0.06 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Meng, F.; Hu, W.; Wang, B.; Luo, X.; Xu, H.; Wan, J.; Xue, W.; Su, Y.; Sun, Y.; Wu, J. Post-Marketing Safety Surveillance of HPV Vaccines in Anhui Province, China, 2017–2024. Vaccines 2025, 13, 846. https://doi.org/10.3390/vaccines13080846
Meng F, Hu W, Wang B, Luo X, Xu H, Wan J, Xue W, Su Y, Sun Y, Wu J. Post-Marketing Safety Surveillance of HPV Vaccines in Anhui Province, China, 2017–2024. Vaccines. 2025; 13(8):846. https://doi.org/10.3390/vaccines13080846
Chicago/Turabian StyleMeng, Fanya, Wenyi Hu, Binbing Wang, Xianwei Luo, Haiyang Xu, Jiangshun Wan, Wenqing Xue, Ying Su, Yong Sun, and Jiabing Wu. 2025. "Post-Marketing Safety Surveillance of HPV Vaccines in Anhui Province, China, 2017–2024" Vaccines 13, no. 8: 846. https://doi.org/10.3390/vaccines13080846
APA StyleMeng, F., Hu, W., Wang, B., Luo, X., Xu, H., Wan, J., Xue, W., Su, Y., Sun, Y., & Wu, J. (2025). Post-Marketing Safety Surveillance of HPV Vaccines in Anhui Province, China, 2017–2024. Vaccines, 13(8), 846. https://doi.org/10.3390/vaccines13080846